|Systematic (IUPAC) name|
|(what is this?)|
Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015[update], it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.
- "CLINICAL TRIALS DATABASE". Menarini Group. Retrieved 11 March 2015.
- H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541.
- S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome.". Drugs of the Future 33 (2): 111–115.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|